Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Common Variable Immunodeficiency A subject is eligible for the study if all of the following are met: Has given written informed consent prior to screening. Is male or female aged 18 through 75 years. Has CVID diagnosed definitively prior to screening (based on the IUIS criteria). Has a documented, unintended loss of greater than 5% of their body weight over the last year or requires nutritional supplements to maintain his/her body weight OR has chronic diarrhea defined as a complaint of liquid stools for at least 4 consecutive weeks (and an output of greater than 200 g stool/24hr on a diet of at least 1600 calories with 60 g fat.) If taking oral antibiotics chronically, must have used a stable dose of the antibiotic continuously for at least 2 weeks prior to start of screening period. Not taking any potential CYP3A4 inhibitors/inducers (e.g., macrolide antibiotics, HIV protease inhibitors, antifungals, grapefruit juice, St. John's Wort)  A subject is excluded from the study if any of the following are met: General Has any clinically significant disease (e.g., renal, hepatic, neurological, cardiovascular, pulmonary, endocrinologic, psychiatric, hematologic, urologic, or other acute or chronic illness) that in the opinion of the investigator would make the subject an unsuitable candidate for this trial. Is a woman who has a positive serum pregnancy test or who is breast-feeding. Is a woman of childbearing potential or a man who does not agree to use two forms of contraception during the course of the study and follow-up period. Has hypersensitivity to any of the components of STA 5326 mesylate drug product. Has any of the following clinical chemistry values: AST greater than 2.5 x upper limit of normal (ULN). ALT greater than 2.5 x ULN. Serum bilirubin greater than 1.5 x ULN. Serum creatinine greater than 1.5 x ULN. Alkaline phosphatase greater than 2.5 x ULN. Has a hemoglobin level less than 9 g/dL or hematocrit less than 30%. Has a Prothromin Time INR greater than 1.3 or a Partial Thromboplastin Time greater than 3 sec compared to control value. Has the following cell counts (cells/microliter): Platelet count less than 90,000 or greater than 800,000. White blood cell count less than 1,500. Neutrophil count less than 900. Has a current infection requiring intravenous antibiotics, a serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia). Has a history of cancer within the past 5 years, with the exception of excised basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ. Had a dependency for any illicit drug, chemical, or alcohol within the past 5 years. Has a history of active tuberculosis (or a CXR with findings suggestive of old TB infection including calcified nodular lesions, apical fibrosis, or pleural scarring), acute or chronic hepatitis B, hepatitis C, or human immunodeficiency virus (HIV). Gastrointestinal Has a stool sample positive for gastrointestinal infection during screening. Has a positive hydrogen breath test Prior Medication Received parenteral corticosteroids within 1 month prior to receiving study drug. The use of short-term or single-dose corticosteroids as a pretreatment regimen for IVIG is acceptable. Received any investigational drug within 3 months prior to receiving study drug. Received cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 2 months prior to receiving study drug. Received any biological product (e.g., infliximab, adalimumab, natalizumab, etc.) within 3 months prior to receiving study drug. Ever received treatment with STA-5326 mesylate, anti-IL 12 antibodies, or other specific IL 12 inhibitors